A new review in Genes & Diseases highlights how the
genetic makeup of lung tumors and their surrounding immune environment can help explain why immunotherapy works well for some patients but offers limited benefit to others. The article outlines opportunities to make treatment selection more precise for
non-small cell lung cancer (NSCLC).
Prepared by a team at the First Hospital of Jilin University, the review brings together evidence on cancer-driving mutations and cellular signaling pathways that influence responses to
immune checkpoint inhibitors. These medicines release molecular brakes on immune cells, helping them recognize and attack cancer. However, tumors can develop ways to evade this response.
The central message is that
tumor genetics and
immune characteristics should be considered together. Measuring
PD-L1, a protein associated with immunotherapy response, provides useful information, but a broader assessment can reveal important differences hidden behind a single biomarker result. Genetic sequencing and immune profiling could support more individualized treatment decisions.
Among the genetic changes discussed, certain
KRAS mutations, particularly when accompanied by
TP53 mutations, are associated with greater immunotherapy benefit. By contrast, common
EGFR mutations and
ALK rearrangements often show limited responses to checkpoint inhibitors used alone. Other alterations, including
STK11 and
KEAP1, can contribute to an immune environment that resists treatment, underscoring the importance of examining combinations of mutations.
The review also explores strategies to reshape the
tumor microenvironment, the network of immune cells, supporting cells and molecules surrounding a tumor. Blocking the
CD73/adenosine pathway could help reduce immune suppression, while activating
STING signaling may strengthen immune recognition. Approaches involving DNA damage repair and other signaling networks offer additional possibilities for improving responses to checkpoint blockade.
Combining immunotherapy with targeted medicines or chemotherapy may offer advantages in selected settings. However, the article emphasizes that combinations require careful evaluation: some pairings can cause substantial
liver toxicity or
lung inflammation. Potential benefit therefore needs to be balanced against treatment risks, mutation subtype and previous therapy.
For patients whose cancer stops responding, the review proposes repeat genetic and biomarker assessment to help identify changes that could inform subsequent treatment choices. Several emerging combinations remain experimental, and their value requires further clinical validation.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to
Genes & Diseases may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (
https://x.com/GenesNDiseases)
# # # # # #
Reference
Chunyan Liu, Shan Zhu, Jing Wu, Yuan Qiao, Ning Yang, Jingtao Chen, Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC, Genes & Diseases, Volume 14, Issue 1, 2027, 102230,
https://doi.org/10.1016/j.gendis.2026.102230
Funding
National Key Research and Development Program (China) 2021YFF0704800
National Natural Science Foundation of China
82273186
National Natural Science Foundation of China
82102714
Scientific and Technological Developing Plan of Jilin Province (China) YDZJ202201ZYTS098
Jilin Provincial Department of Education Scientific Research Project (China) JJKH20231213KJ
Jilin Provincial Specialized Fund for Medical and Health Talents (China) JLSWSRCZX2023-111